Marinus Pharmaceuticals (MRNS) Key Ratios

$0.55

$0.00 (0.00%)

As on 11-Feb-2025 09:30EDT

Market cap

info icon

$30 Mln

Revenue (TTM)

info icon

$31 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

3.2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 6.02 16.39 1.63 26.97 --
EBIT 32.03 33.36 -2.82 -17.04 -188.26
Net Profit 32.39 26.53 -5.01 -26.17 -197.42
EPS 32.58 30.78 6.86 0.04 5.97
Book Value -- -- -88.53 -59.06 -43.66
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -352.07-1,252.66-394.77-406.75-22.59
Net Margin info -368.95-5,414.41-446.49---78.84
Return on equity info -114.34-94.23---213.02-23.38
Return on Capital info -63.65-63.73---89.55-13.98
Return on Assets info -48.82-52.34-85.28-65.70-10.00
Debt to Equity (x) info -----0.636.580.63
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
-89.55
-13.98
-87.43
-59.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
-213.02
-23.38
-106.63
-59.25
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-85.28

Lower than Peers by 88.14

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-85.28
-65.70
-10.00
-70.77
-53.46
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-394.77

Lower than Peers by 410.59

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-394.77
-406.75
-22.59
-626.88
-3,954.42
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-446.49

Lower than Peers by 454.72

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-446.49
-456.31
-78.84
-659.06
-3,056.97
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

1.63

Lower than Peers by 6.42

Year on year growth in net sales

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
1.63
0.22
0.66
7.93
--
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-2.82

Lower than Peers by 11.09

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-2.82
-2,090.23
94.02
-41.59
-25.08
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-5.01

Lower than Peers by 12.74

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-5.01
-613.59
80.51
-52.55
-23.95
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

6.86

Lower than Peers by 3.53

Year on year growth in earnings per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
6.86
-4.66
0.84
-0.32
0.16
Peer Median
10.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-215.30

Lower than Peers by 220.17

Year on year growth in book value per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-215.30
--
--
--
--
Peer Median
4.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

-0.63

Lower than Peers by 1.23

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-0.63
6.58
0.63
0.77
0.00
Peer Median
0.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-0.21

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-0.21
0.87
0.01
0.01
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.66

Higher than Peers by 0.01

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
1.66
4.07
4.38
3.03
13.06
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.47

Higher than Peers by 0.27

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
1.47
4.01
4.38
3.26
13.65
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-7.21

Lower than Peers by 11.98

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-7.21
-7.46
-0.54
-37.26
-136.15
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

12.20

Lower than Peers by 9.07

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
12.20
12.26
24.92
20.76
95.81
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.19

Lower than Peers by 0.21

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
0.19
0.14
0.13
0.11
0.01
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
59.80
68.34
57.51
349.94
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
235.13
-4,958.27
-1,926.58
-45.44
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
799.24
4,075.22
659.45
17.99
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
-504.32
-8,965.15
-2,528.53
286.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
-4.36
-9.03
-4.29
-5.83
Peer Median
37.91
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

3.17

Lower than Peers by 4.52

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
3.17
36.76
1.54
8.16
2.83
Peer Median
7.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
--
--
--
--
--
Peer Median
0.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-34.47

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
-34.47
-4.59
-2.19
-3.72
-3.68
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

30

Lower than Peers by 2,539

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Marinus Pharmaceuticals (MRNS)
30
--
--
--
--
Peer Median
2,569
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...